NCT07031219 HIV/HBV/HCV Triple Screening in Primary Care
| NCT ID | NCT07031219 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Texas Southwestern Medical Center |
| Condition | HIV |
| Study Type | INTERVENTIONAL |
| Enrollment | 50 participants |
| Start Date | 2026-11-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 50 participants in total. It began in 2026-11-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Design: This will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Study participants will be primary care providers. For each participating provider, their encounter will be randomized to either control (no alert; no changes to EMR interface) or an alert with triple-testing order panel intervention arm (alert linked to order panel with screening tests for all three bloodborne viruses (BBVs) selected by default; the alert will be triggered when a provider attempts to order a screening test for at least one BBV). The alert linked to triple testing orders will only be triggered if the provider orders a virus BBV screening test based on their normal practice and standard of care for their patient. Providers will see which orders are selected prior to signing (finalizing) them; therefore, this study will be unblinded. To mitigate the effect of unblinding, randomization will occur at the encounter level which will lead to providers experiencing both the control and intervention conditions randomly throughout the duration of the study. Outcomes/endpoints: The investigators will compare incidences of HIV, HBV, and HCV diagnoses between the two encounter conditions, estimate number of cases missed by not triple-testing, estimate laboratory costs per condition, and measure patient encounters per condition.
Eligibility Criteria
Inclusion Criteria: * Outpatient primary care adult providers at participating institutions * Providers who provide consent to participate in this study. * Providers must intend to continue their current practice for at least 12 months. * Providers with at least 12 months experience in their current practice. Exclusion Criteria: * Providers who do not consent to participate * Sub-specialty providers * Pediatric providers * Providers who anticipate leaving their current practice within the next 12 months (i.e. providers who plan to retire, move, etc.). * Providers with less than 12 months experience in their current practice (i.e. new providers or trainees who joined the practice within the last year) * Note: family medicine and med/peds providers can participate, but only for their adult patients. The intervention alert+order panel and any data collection will be restricted to adult patients ≥ 18 years old.
Contact & Investigator
Mamta K Jain, MD, MPH
PRINCIPAL INVESTIGATOR
University of Texas Southwestern Medical Center
Frequently Asked Questions
Who can join the NCT07031219 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying HIV. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07031219 currently recruiting?
Yes, NCT07031219 is actively recruiting participants. Contact the research team at nicole.naiman@utsouthwestern.edu for enrollment information.
Where is the NCT07031219 trial being conducted?
This trial is being conducted at Dallas, United States.
Who is sponsoring the NCT07031219 clinical trial?
NCT07031219 is sponsored by University of Texas Southwestern Medical Center. The principal investigator is Mamta K Jain, MD, MPH at University of Texas Southwestern Medical Center. The trial plans to enroll 50 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.